Jane Byram News Today

Elden Sternat age 85 of New Hampton, IA, died Friday, August 12, 2022, at Linn Haven Rehab & Healthcare in New Hampton.

Combination Accelerates Outcomes in Early Drug Discovery X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule

Noxopharm’s Veyonda to Begin First-Line Sarcoma Treatment Testing FDA IND Approval Leads to CEP-2 Kickoff SYDNEY--(BUSINESS WIRE)--#Veyonda--Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) today announced its CEP-2 study will begin shortly. CEP-2 is related to the Investigational New Drug (IND) approval of Veyonda ® by the FDA based on evidence that Veyonda may increase generally poor response rates of sarcoma cancers to chemotherapy in combination with common ...

X-Chem Announces OpenDEX DNA-Encoded Library Screening Search jobs Flexible and Cost-Effective Solution for Screening Billions of Small Molecules WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, the industry-leading provider of DNA-encoded library (DEL)-based discovery services, today announced the global launch of its OpenDEX solution. This new offering provides flexible access to the high-quality libraries, experienced DEL operators and powerful informatic tools that make up the X-Chem discovery pla...

Noxopharm Limited: Clinical Data Shows Noxopharms Veyonda May Prevent Cytokine Storm Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease. "Until enough people are vaccinated to achieve global herd immunity in the face of ...

Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm on April 27 2021 10:00 PM SYDNEY--(BUSINESS WIRE)--#Veyonda--Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease. “Until enough people are vaccinate...

Noxopharm Files Septic Shock Treatment Patent for Veyonda® New indication doubles the commercial opportunity SYDNEY--(BUSINESS WIRE)--#Veyonda--Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda ® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses. Overall, septic shock is believe...